Clinical Trials

Twitter

Facebook

Copy Link

Key Facts

Use CasesPatient Matching, Site Selection

Key PlayersTempus, Unlearn.ai, Medidata

Top News

Abridge and Nvidia build foundation model for clinical intelligence from real doctor visits

Abridge unveiled an AI-native clinician intelligence platform with backing from Nvidia and Eli Lilly, transforming ambient AI from a transcription tool into an operating system for medicine. The startup now processes 100 million clinical conversations annually across 300+ health systems, while co-developing the first foundation model trained specifically on doctor-patient dialogue.

Health3 sources

Abridge and Nvidia build foundation model for clinical intelligence from real doctor visits

Health3 sources

New AI technology speeds eye disease diagnosis and predicts heart attack, stroke risks from retinal scans

Researchers at Washington University School of Medicine developed OCTCube-M, an AI system that analyzes 3D eye scans to detect retinal diseases more accurately than older models. The technology identified 43 to 60 additional cases per 1,000 individuals and can predict broader health risks including heart attack, stroke, and kidney failure based solely on retinal imaging.

Health2 sources

New AI technology speeds eye disease diagnosis and predicts heart attack, stroke risks from retinal scans

Health2 sources

Sanofi and Owkin deepen AI partnership with five-year K Pro license for drug development

Sanofi and Owkin have expanded their multi-year partnership to co-develop AI-driven biopharma agents through a five-year license for K Pro, Owkin's AI Scientist platform. The collaboration builds on their 90 million euro strategic partnership that began in 2021, focusing on oncology and immunology research. The new initiative aims to automate complex pharmaceutical research tasks across the drug development pipeline.

Technology2 sources

Sanofi and Owkin deepen AI partnership with five-year K Pro license for drug development

Technology2 sources

AI-designed vaccine passes first human trial, offering broad protection against coronaviruses

Researchers at the University of Cambridge successfully tested the world's first AI-designed vaccine in humans. The trial involved 39 volunteers and targeted multiple coronaviruses, including COVID-19 and SARS. The vaccine uses an AI-designed super-antigen that could provide lasting protection against entire virus families, even as they mutate, potentially transforming how we prepare for future pandemics.

Health11 sources

AI-designed vaccine passes first human trial, offering broad protection against coronaviruses

Health11 sources

AI Diagnosis Outperforms Emergency Room Doctors in Harvard Study, Raises Questions on Patient Care

A Harvard Medical School study published in Science reveals that OpenAI's o1 model achieved 67% diagnostic accuracy at emergency room triage, outperforming two attending physicians who scored 55% and 50%. The research tested AI against doctors using real patient data from Beth Israel Deaconess Medical Center, with blinded reviewers unable to distinguish AI output from human diagnoses. While the findings demonstrate AI's potential as a diagnostic tool, researchers emphasize the urgent need for clinical trials and accountability frameworks before deployment in actual patient care settings.

Science16 sources

AI Diagnosis Outperforms Emergency Room Doctors in Harvard Study, Raises Questions on Patient Care

Science16 sources

FDA deploys AI to monitor clinical trials in real time, cutting drug development by up to 40%

The FDA announced its first real-time clinical trials using AI to track patient safety and effectiveness data as it's collected. The initiative could reduce drug development time by 20-40% by eliminating administrative delays that currently consume 45% of the timeline between Phase 1 trials and FDA submissions.

Policy2 sources

FDA deploys AI to monitor clinical trials in real time, cutting drug development by up to 40%

Policy2 sources

AI detects pancreatic cancer up to 3 years before diagnosis, outperforming radiologists by nearly 3x

Mayo Clinic researchers developed REDMOD, an AI model that spots pancreatic cancer an average of 475 days before clinical diagnosis by identifying subtle changes invisible to the human eye on routine CT scans. The system correctly identified 73% of cases compared to 39% for radiologists, offering hope for shifting diagnosis from late-stage terminal disease to early-stage curative treatment.

Health9 sources

AI detects pancreatic cancer up to 3 years before diagnosis, outperforming radiologists by nearly 3x

Health9 sources

AI analyzes facial aging to predict cancer survival, revealing how treatment accelerates biological age

Researchers at Mass General Brigham developed an AI tool that tracks biological age through facial photographs, finding cancer patients age 40% faster than expected. The Face Aging Rate metric, published in Nature Communications, offers a non-invasive biomarker to guide personalized treatment planning and predict survival outcomes in oncology.

Health4 sources

AI analyzes facial aging to predict cancer survival, revealing how treatment accelerates biological age

Health4 sources

Johnson & Johnson uses AI to slash drug development lead time by half

Johnson & Johnson is deploying artificial intelligence to cut drug development lead optimization time in half, according to CIO Jim Swanson. The pharmaceutical giant is also using AI to reduce clinical trial report preparation from 700 hours to just 15 minutes and optimize manufacturing processes, marking a significant shift in how the company approaches cancer treatment development.

Technology3 sources

Johnson & Johnson uses AI to slash drug development lead time by half

Technology3 sources

Stanford Professor James Zou targets $1 billion valuation for AI physiology startup

Stanford's James Zou is raising approximately $100 million at a $1 billion valuation for Human Intelligence, an AI startup focused on human physiology research. The company builds on Zou's decade of research, including FDA-cleared cardiac AI and disease prediction models that analyze sleep data to detect conditions years before symptoms appear.

Startups2 sources

Stanford Professor James Zou targets $1 billion valuation for AI physiology startup

Startups2 sources

Amazon Bio Discovery uses AI to compress 18-month drug research timelines into weeks

Amazon Web Services unveiled Amazon Bio Discovery, an AI-powered platform that enables scientists to run complex computational workflows for early-stage drug discovery without coding expertise. The tool provides access to over 40 specialized biological foundation models and can generate 300 drug candidates in weeks versus 18 months using traditional methods.

Technology7 sources

Amazon Bio Discovery uses AI to compress 18-month drug research timelines into weeks

Technology7 sources

AI-led selloff in contract research firms may overestimate disruption risk to CRO industry

Shares of contract research organizations like IQVIA, Medpace, and Charles River Laboratories tumbled after Anthropic's February AI agent launch sparked fears drugmakers could bring clinical trial work in-house. But industry experts argue the selloff misjudges how far artificial intelligence can replace core CRO capabilities like patient recruitment and global trial execution.

Business2 sources

AI-led selloff in contract research firms may overestimate disruption risk to CRO industry

Business2 sources

Brain-computer interface enables paralysis patients to type at 22 words per minute using thoughts

A breakthrough brain implant for paralysis allowed two participants to type using their thoughts at speeds reaching 22 words per minute with just 1.6% error rate. The BrainGate system translates neural signals into text by decoding intended finger movements on a virtual QWERTY keyboard, bringing assistive communication technology closer to real-time conversation speeds for people with severe motor impairments.

Science2 sources

Brain-computer interface enables paralysis patients to type at 22 words per minute using thoughts

Science2 sources

AI boosts breast cancer detection by 10% in major UK screening studies, flags hidden cancers

Major UK studies show AI integration into breast cancer screening increases detection rates by 10.4% and identifies up to 27.5% of interval cancers before they become visible. The technology also reduces radiologist workload by up to 44% while maintaining accuracy across diverse populations, marking a shift in how screening programs could operate.

Health6 sources

AI boosts breast cancer detection by 10% in major UK screening studies, flags hidden cancers

Health6 sources

China targets widespread brain-computer interface adoption within 3-5 years as BCI tech race heats up

China could see brain-computer interface technology move into practical public use within three to five years, according to leading BCI expert Yao Dezhong. Beijing has elevated BCIs to a core strategic industry in its new five-year plan, placing the technology alongside quantum computing, embodied AI, and 6G as it races to catch up with U.S. competitors like Neuralink.

Policy4 sources

China targets widespread brain-computer interface adoption within 3-5 years as BCI tech race heats up

Policy4 sources

Prev 123 Next